PURPOSE: To evaluate the activity of panobinostat in refractory renal carcinoma. PATIENTS AND METHODS: Patients with advanced clear cell renal carcinoma who had received previous therapy with at least one angiogenesis inhibitor and one mTOR inhibitor were treated with panobinostat 45 mg orally twice a week, and were reevaluated after 8 weeks. RESULTS: Twenty patients were treated with no objective responses. All patients progressed or stopped treatment prior to the 16-week reevaluation. Panobinostat was generally well-tolerated. CONCLUSION: Panobinostat had no activity in this group of patients with refractory renal carcinoma. Further development of panobinostat in renal carcinoma is not recommended.
PURPOSE: To evaluate the activity of panobinostat in refractory renal carcinoma. PATIENTS AND METHODS: Patients with advanced clear cell renal carcinoma who had received previous therapy with at least one angiogenesis inhibitor and one mTOR inhibitor were treated with panobinostat 45 mg orally twice a week, and were reevaluated after 8 weeks. RESULTS: Twenty patients were treated with no objective responses. All patients progressed or stopped treatment prior to the 16-week reevaluation. Panobinostat was generally well-tolerated. CONCLUSION:Panobinostat had no activity in this group of patients with refractory renal carcinoma. Further development of panobinostat in renal carcinoma is not recommended.
Authors: John H Strickler; Alexander N Starodub; Jingquan Jia; Kellen L Meadows; Andrew B Nixon; Andrew Dellinger; Michael A Morse; Hope E Uronis; P Kelly Marcom; S Yousuf Zafar; Sherri T Haley; Herbert I Hurwitz Journal: Cancer Chemother Pharmacol Date: 2012-06-29 Impact factor: 3.333
Authors: Belamy B Cheung; Owen Tan; Jessica Koach; Bing Liu; Michael S Y Shum; Daniel R Carter; Selina Sutton; Sela T Po'uha; Louis Chesler; Michelle Haber; Murray D Norris; Maria Kavallaris; Tao Liu; Geraldine M O'Neill; Glenn M Marshall Journal: Mol Oncol Date: 2015-04-29 Impact factor: 6.603
Authors: Eric Jonasch; P Andrew Futreal; Ian J Davis; Sean T Bailey; William Y Kim; James Brugarolas; Amato J Giaccia; Ghada Kurban; Armin Pause; Judith Frydman; Amado J Zurita; Brian I Rini; Pam Sharma; Michael B Atkins; Cheryl L Walker; W Kimryn Rathmell Journal: Mol Cancer Res Date: 2012-05-25 Impact factor: 5.852
Authors: Katharine A Collier; Hugo Valencia; Herbert Newton; Erinn M Hade; Douglas W Sborov; Robert Cavaliere; Ming Poi; Mitch A Phelps; Sophia G Liva; Christopher C Coss; Jiang Wang; Soun Khountham; Paul Monk; Charles L Shapiro; Richard Piekarz; Craig C Hofmeister; D Bradley Welling; Amir Mortazavi Journal: Cancer Chemother Pharmacol Date: 2021-01-25 Impact factor: 3.333